SEHK:2171Biotechs
CARsgen Therapeutics Holdings (SEHK:2171) Gains Clinical Momentum Following Satri Cel Trial Update But Looks Pricey
CARsgen Therapeutics Holdings (SEHK:2171) drew fresh attention after reporting preliminary positive results from a Chinese investigator initiated trial of its Claudin18.2 CAR T therapy, satri cel, which has been accepted for poster presentation at ESMO 2026.
See our latest analysis for CARsgen Therapeutics Holdings.
At a share price of HK$14.77, CARsgen Therapeutics Holdings has recently combined a 12.32% 1 month share price return with a 38.92% decline over 3 months and a 38.97% fall in the...